A Repeat Dose, Open Label, Two Period, Randomized, Cross Over Study to Compare the Effect of Daprodustat to Recombinant, Human Erythropoietin (rhEPO) on Oral Iron Absorption in Adult Participants With Anemia Associated With Chronic Kidney Disease Who Are Not on Dialysis
Not yet recruiting
Phase of Trial: Phase II/III
Latest Information Update: 17 Jan 2019
At a glance
- Drugs Daprodustat (Primary) ; Ferrous sulfate; Recombinant erythropoietin
- Indications Anaemia
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline
- 08 Jan 2019 Planned End Date changed from 14 Jun 2019 to 6 Sep 2019.
- 08 Jan 2019 Planned primary completion date changed from 14 Jun 2019 to 6 Sep 2019.
- 08 Jan 2019 Planned initiation date changed from 30 Nov 2018 to 15 Feb 2019.